Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q1 2025 (March 31)10holders
2new positions
2sold out
$1.41avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, unchanged from Q4 2024. 2 opened new positions and 2 sold out. The largest holders were Absolute Investment Advisers, LLC ($15.4M), Angelo Gordon & Co., L.P. ($14.4M) and Ofi Invest Asset Management ($8.8M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $5.2M |
| Exits | 2 | $4.0M |
All 13F filers, Q4 2024 → Q1 2025: 2,584,151 shares bought and 3,752,000 shares sold, net −1,167,849 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Absolute Investment Advisers, LLC | 2.25% | No change | 12,000,000 | $15.4M |
| Angelo Gordon & Co., L.P. | 3.03% | Add +28.6% | 11,250,000 | $14.4M |
| Ofi Invest Asset Management | 0.23% | No change | 7,400,000 | $8.8M |
| Nomura Holdings Inc. | 0.03% | New | 78,581 | $5.0M |
| Sonora Investment Management Group, LLC | 0.23% | Reduce -0.2% | 2,275,000 | $2.9M |
| Bank of New York Mellon Corp | 0.00% | No change | 1,200,000 | $1.5M |
| Sei Investments Co. | 0.00% | No change | 322,000 | $412K |
| Loomis Sayles & Co. L P | 0.00% | New | 3,570 | $228K |
| Oppenheimer Asset Management Inc. | 0.00% | Add +1.2% | 164,000 | $210K |
| Stephens Inc. | 0.00% | No change | 50,000 | $64K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.